Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
>,19561037,time,"In the 0.75-mg group, we observed a significantly longer time to treatment failure than in the 0.075-mg group (median time >120 versus 82.0 h, P = 0.038).",A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19561037/),h,120,8211,DB00377,Palonosetron
,19561037,time,"In the 0.75-mg group, we observed a significantly longer time to treatment failure than in the 0.075-mg group (median time >120 versus 82.0 h, P = 0.038).",A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19561037/),h,82.0,8212,DB00377,Palonosetron
,15102873,total body clearance,"Mean total body clearance, elimination half-life, and apparent volume of distribution ranged from 1.11 to 3.90 mL/min/kg, 33.7 to 54.1 hours, and 3.85 to 12.6 L/kg, respectively, in U.S. subjects and from 2.58 to 3.50 mL/min/kg, 30.8 to 36.8 hours, and 6.96 to 9.85 L/kg, respectively, in Japanese subjects.","Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102873/),[ml] / [kg·min],1.11 to 3.90,13800,DB00377,Palonosetron
,15102873,elimination half-life,"Mean total body clearance, elimination half-life, and apparent volume of distribution ranged from 1.11 to 3.90 mL/min/kg, 33.7 to 54.1 hours, and 3.85 to 12.6 L/kg, respectively, in U.S. subjects and from 2.58 to 3.50 mL/min/kg, 30.8 to 36.8 hours, and 6.96 to 9.85 L/kg, respectively, in Japanese subjects.","Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102873/),[l] / [kg],3,13801,DB00377,Palonosetron
,15102873,apparent volume of distribution,"Mean total body clearance, elimination half-life, and apparent volume of distribution ranged from 1.11 to 3.90 mL/min/kg, 33.7 to 54.1 hours, and 3.85 to 12.6 L/kg, respectively, in U.S. subjects and from 2.58 to 3.50 mL/min/kg, 30.8 to 36.8 hours, and 6.96 to 9.85 L/kg, respectively, in Japanese subjects.","Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102873/),[l] / [kg],3,13802,DB00377,Palonosetron
,15102873,half-life,"The plasma concentration profile of palonosetron, as represented by a half-life of approximately 40 hours, may provide a clinical advantage over other 5-HT(3) antagonists.","Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102873/),h,40,13803,DB00377,Palonosetron
,24590375,accumulation ratios,"The accumulation ratios for C max and AUClast after the second dose on day 3 were 1.42 and 1.37, respectively.",Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24590375/),,1.42,31308,DB00377,Palonosetron
,24590375,accumulation ratios,"The accumulation ratios for C max and AUClast after the second dose on day 3 were 1.42 and 1.37, respectively.",Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24590375/),,1.37,31309,DB00377,Palonosetron
,24590375,complete response (CR) rate,"Almost all of the patients had no nausea or vomiting in the acute phase (complete response (CR) rate, 96.2% [25/26]; CP rate, 92.3% [24/26]).",Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24590375/),%,96,31310,DB00377,Palonosetron
,27186139,maximum granisetron plasma concentrations,"Mean maximum granisetron plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively.","Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186139/),[ng] / [ml],10.8,35192,DB00377,Palonosetron
,27186139,maximum granisetron plasma concentrations,"Mean maximum granisetron plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively.","Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186139/),[ng] / [ml],17.8,35193,DB00377,Palonosetron
,27186139,half-lives,"Mean maximum granisetron plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively.","Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186139/),h,30.8,35194,DB00377,Palonosetron
,27186139,half-lives,"Mean maximum granisetron plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively.","Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27186139/),h,35.9,35195,DB00377,Palonosetron
,15831783,terminal phase elimination half-life,Mean terminal phase elimination half-life after day 3 dosing was 42.8 hours.,Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831783/),h,42.8,35655,DB00377,Palonosetron
,15831783,elimination half-life,"The 2.1-fold accumulation of palonosetron in plasma following 3 daily doses was predictable based on elimination half-life of approximately 40 hours, and the maximum plasma concentration remained below the maximum plasma concentration previously observed after a single, well-tolerated 0.75 mg intravenous bolus dose of palonosetron.",Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831783/),h,40,35656,DB00377,Palonosetron
,33386423,maximum plasma concentration (Cmax),"Netupitant mean maximum plasma concentration (Cmax) [± standard deviation] of 698 ± 217 ng/mL was reached at 3-6 h, with a mean total exposure (AUC0-inf) of 22,000 ± 4410 h·ng/mL.","A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386423/),[ng] / [ml],698,54957,DB00377,Palonosetron
,33386423,total exposure (AUC0-inf),"Netupitant mean maximum plasma concentration (Cmax) [± standard deviation] of 698 ± 217 ng/mL was reached at 3-6 h, with a mean total exposure (AUC0-inf) of 22,000 ± 4410 h·ng/mL.","A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386423/),[h·ng] / [ml],"22,000",54958,DB00377,Palonosetron
,33386423,Cmax,"For palonosetron, a mean Cmax of 1.8 ± 0.252 ng/mL was reached at 2-6 h postadministration, with a mean AUC0-inf of 81.0 ± 14.0 h·ng/mL.","A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386423/),[ng] / [ml],1.8,54959,DB00377,Palonosetron
,33386423,AUC0-inf,"For palonosetron, a mean Cmax of 1.8 ± 0.252 ng/mL was reached at 2-6 h postadministration, with a mean AUC0-inf of 81.0 ± 14.0 h·ng/mL.","A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386423/),[h·ng] / [ml],81.0,54960,DB00377,Palonosetron
,30607545,Cmax,Values for aprepitant group vs. control group were as follows: geometric mean of Cmax was 119 vs.,"Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,119,64315,DB00377,Palonosetron
,30607545,AUC0-last,"120 ng/mL, AUC0-last was 648 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,648,64316,DB00377,Palonosetron
,30607545,AUC0-inf,"635 ng h/mL, AUC0-inf was 681 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,681,64317,DB00377,Palonosetron
,30607545,plasma clearance,"668 ng h/mL, plasma clearance was 4.40 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,4.40,64318,DB00377,Palonosetron
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.11,64319,DB00377,Palonosetron
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.25,64320,DB00377,Palonosetron
,16988202,AUC(0-infinity),"Palonosetron infused over 15 minutes is well tolerated, with an AUC(0-infinity) equivalent to a 30-second infusion.",Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988202/),second,30,65235,DB00377,Palonosetron
,24122871,C90%,"The netupitant minimal plasma concentration predicted to achieve a NK1 -RO of 90%, C90% , in the striatum was 225 ng/mL; after administration of netupitant 300 mg, concentrations exceeded the C90% .",Netupitant PET imaging and ADME studies in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122871/),[ng] / [ml],225,80725,DB00377,Palonosetron
>,24122871,Elimination,Elimination of >90% was predicted at day 29 and was principally via hepatic/biliary route (>85%) with a minor contribution of the renal route (<5%).,Netupitant PET imaging and ADME studies in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122871/),%,90,80726,DB00377,Palonosetron
,14760130,plasma half-life,Dose-proportional increases in pharmacokinetic parameters and a long plasma half-life (43.7-128 h) were observed.,"Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14760130/),h,43.7-128,87971,DB00377,Palonosetron
,30685793,time to first treatment failure,The mean time to first treatment failure for the 1.5% of NEPA-treated patients without complete response receiving highly emetogenic chemotherapy was 8 h.,"Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30685793/),h,8,99100,DB00377,Palonosetron
,27294531,flow rate,"Following liquid-liquid extraction, the compounds were eluted isocratically on a Phenomenex C18 column (50mm×2.0mm, 3μm) with the mobile phase consisting of acetonitrile and 10mM ammonium acetate buffer (pH 9.0) (89:11, v/v) at the flow rate of 0.3mL/min.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),[ml] / [min],0.3,109085,DB00377,Palonosetron
,27294531,m/,"The monitored ion transitions were m/z 579.5→522.4 for netupitant, m/z 297.3→110.2 for palonosetron and m/z 441.2→138.1 for IS.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),,579.5,109086,DB00377,Palonosetron
,27294531,m/z,"The monitored ion transitions were m/z 579.5→522.4 for netupitant, m/z 297.3→110.2 for palonosetron and m/z 441.2→138.1 for IS.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),,297.3,109087,DB00377,Palonosetron
,27294531,m/z,"The monitored ion transitions were m/z 579.5→522.4 for netupitant, m/z 297.3→110.2 for palonosetron and m/z 441.2→138.1 for IS.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),,110.2,109088,DB00377,Palonosetron
,27294531,m/z,"The monitored ion transitions were m/z 579.5→522.4 for netupitant, m/z 297.3→110.2 for palonosetron and m/z 441.2→138.1 for IS.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),,441.2,109089,DB00377,Palonosetron
,27294531,m/z,"The monitored ion transitions were m/z 579.5→522.4 for netupitant, m/z 297.3→110.2 for palonosetron and m/z 441.2→138.1 for IS.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),,138.1,109090,DB00377,Palonosetron
,27294531,Ch,"Chromatographic run time was 2.5min per injection, which made it possible to analyze more than 300 of samples per day.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),[min] / [injection],2.5,109091,DB00377,Palonosetron
,27294531,run time,"Chromatographic run time was 2.5min per injection, which made it possible to analyze more than 300 of samples per day.",Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294531/),[min] / [injection],2.5,109092,DB00377,Palonosetron
,24587006,AUC0-24h,AUC0-24h for IV and SC palonosetron were respectively 14.1 and 12.7 ng × h/ml (p=0.160).,Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24587006/),[h·ng] / [ml],14.1,126404,DB00377,Palonosetron
,24587006,AUC0-24h,AUC0-24h for IV and SC palonosetron were respectively 14.1 and 12.7 ng × h/ml (p=0.160).,Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24587006/),[h·ng] / [ml],12.7,126405,DB00377,Palonosetron
,24587006,Bioavalability,Bioavalability of SC palonosetron was 118% (95% IC: 69-168).,Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24587006/),%,118,126406,DB00377,Palonosetron
,22465199,ch,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),min,5.5,132710,DB00377,Palonosetron
,22465199,run time,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),min,5.5,132711,DB00377,Palonosetron
,22465199,LOD,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),[ng] / [ml],0.003,132712,DB00377,Palonosetron
more,22465199,recovery rates,The recovery rates of palonosetron and IS both for plasma and urine were more than 90%.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),%,90,132713,DB00377,Palonosetron
,22465199,urine accumulated excretory rate,The mean urine accumulated excretory rate was 25.97 ± 12.87%.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),%,25.97,132714,DB00377,Palonosetron
,21937184,flow-rate,"Chromatographic separation was carried out on an ACQUITY UPLC™ HSS T(3) column with mobile phase consisting of methanol-water containing 0.1% formic acid (80:20, v/v) at a flow-rate of 0.20mL/min.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),[ml] / [min],0.20,163769,DB00377,Palonosetron
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,297.3,163770,DB00377,Palonosetron
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,109.8,163771,DB00377,Palonosetron
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,455.1,163772,DB00377,Palonosetron
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,164.9,163773,DB00377,Palonosetron
,15139789,terminal elimination half-life,"Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding.",Palonosetron. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139789/),h,40,174042,DB00377,Palonosetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,40,174671,DB00377,Palonosetron
,15899109,plasma elimination half-life,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),h,43,174672,DB00377,Palonosetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],130,174673,DB00377,Palonosetron
,15899109,total body clearance,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),[ml] / [min],136,174674,DB00377,Palonosetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,410.9,174675,DB00377,Palonosetron
,15899109,volume of distribution at steady-state,"With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3.0 hours; p = 0.348), mean total body clearance was 130 mL/min and 136 mL/min (difference: -5.6 mL/min; p = 0.735), and mean volume of distribution at steady-state was 410.9 L and 442.3 L (difference: -31.4 L; p = 0.463).",Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15899109/),l,442.3,174676,DB00377,Palonosetron
,30412271,absolute bioavailability,"netupitant and palonosetron have high absolute bioavailability (63%-87% and 97%, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),%,63,182030,DB00377,Palonosetron
,30412271,absolute bioavailability,"netupitant and palonosetron have high absolute bioavailability (63%-87% and 97%, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),%,87,182031,DB00377,Palonosetron
,30412271,absolute bioavailability,"netupitant and palonosetron have high absolute bioavailability (63%-87% and 97%, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),%,97,182032,DB00377,Palonosetron
,30412271,volumes of distribution,"Both drugs have large volumes of distribution (cancer patients: 1656-2257 L and 483-679 L, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),l,1656-2257,182033,DB00377,Palonosetron
,30412271,volumes of distribution,"Both drugs have large volumes of distribution (cancer patients: 1656-2257 L and 483-679 L, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),l,483-679,182034,DB00377,Palonosetron
,30412271,systemic clearances,"Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),[l] / [h],19.5-20.8,182035,DB00377,Palonosetron
,30412271,half-lives,"Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),[l] / [h],19.5-20.8,182036,DB00377,Palonosetron
,30412271,half-lives,"Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),h,56.0-93.8,182037,DB00377,Palonosetron
,30412271,half-lives,"Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),[l] / [h],7.0-11.3,182038,DB00377,Palonosetron
,30412271,half-lives,"Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively).",Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412271/),h,43.8-65.7,182039,DB00377,Palonosetron
,15378559,distribution volume,"Radiolabeled metabolic characterization revealed that unchanged palonosetron accounted for 71.9% of the total radioactivity in plasma over 96 h, with an extensive distribution volume (8.34 l/kg) and mean plasma elimination half-life of 37 h.","Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15378559/),[l] / [kg],8.34,184249,DB00377,Palonosetron
,15378559,plasma elimination half-life,"Radiolabeled metabolic characterization revealed that unchanged palonosetron accounted for 71.9% of the total radioactivity in plasma over 96 h, with an extensive distribution volume (8.34 l/kg) and mean plasma elimination half-life of 37 h.","Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15378559/),h,37,184250,DB00377,Palonosetron
,15378559,blood to plasma concentration ratio of,"The blood to plasma concentration ratio of the total radioactivity was 1.2, on average, indicating little selective partitioning in erythrocytes.","Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15378559/),,1.2,184251,DB00377,Palonosetron
,33581259,maximum values (Cmax),"After administration of a single oral dose of 0.25mg, 0.5mg, or 0.75mg palonosetron in Chinese male and female healthy subjects, plasma palonosetron concentrations reached maximum values (Cmax) of 673 ± 151 pg/mL, 1330 ± 258 pg/mL, and 1990 ± 490 pg/mL, respectively, at 3-5 h (tmax).","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),[pg] / [ml],673,192298,DB00377,Palonosetron
,33581259,maximum values (Cmax),"After administration of a single oral dose of 0.25mg, 0.5mg, or 0.75mg palonosetron in Chinese male and female healthy subjects, plasma palonosetron concentrations reached maximum values (Cmax) of 673 ± 151 pg/mL, 1330 ± 258 pg/mL, and 1990 ± 490 pg/mL, respectively, at 3-5 h (tmax).","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),[pg] / [ml],1330,192299,DB00377,Palonosetron
,33581259,maximum values (Cmax),"After administration of a single oral dose of 0.25mg, 0.5mg, or 0.75mg palonosetron in Chinese male and female healthy subjects, plasma palonosetron concentrations reached maximum values (Cmax) of 673 ± 151 pg/mL, 1330 ± 258 pg/mL, and 1990 ± 490 pg/mL, respectively, at 3-5 h (tmax).","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),[pg] / [ml],1990,192300,DB00377,Palonosetron
,33581259,tmax,"After administration of a single oral dose of 0.25mg, 0.5mg, or 0.75mg palonosetron in Chinese male and female healthy subjects, plasma palonosetron concentrations reached maximum values (Cmax) of 673 ± 151 pg/mL, 1330 ± 258 pg/mL, and 1990 ± 490 pg/mL, respectively, at 3-5 h (tmax).","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),h,3-5,192301,DB00377,Palonosetron
,33581259,plasma elimination half-life,"The plasma elimination half-life for 0.25, 0.5 and 0.75 mg of palonosetron was 41.8±9.72 hours, 44.6±8.59 hours and 42.3±8.51 hours, respectively.","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),h,41.8,192302,DB00377,Palonosetron
,33581259,plasma elimination half-life,"The plasma elimination half-life for 0.25, 0.5 and 0.75 mg of palonosetron was 41.8±9.72 hours, 44.6±8.59 hours and 42.3±8.51 hours, respectively.","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),h,44.6,192303,DB00377,Palonosetron
,33581259,plasma elimination half-life,"The plasma elimination half-life for 0.25, 0.5 and 0.75 mg of palonosetron was 41.8±9.72 hours, 44.6±8.59 hours and 42.3±8.51 hours, respectively.","Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33581259/),h,42.3,192304,DB00377,Palonosetron
,30976908,clearance,"In a patient with LBW of 40 kg, typical clearance and central volume of distribution were 0.102 L/min and 6.98 L, respectively.",Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30976908/),[l] / [min],0.102,197270,DB00377,Palonosetron
,30976908,central volume of distribution,"In a patient with LBW of 40 kg, typical clearance and central volume of distribution were 0.102 L/min and 6.98 L, respectively.",Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30976908/),l,6.98,197271,DB00377,Palonosetron
,31404621,Cmax,"Netupitant was rapidly released from its prodrug and Cmax of 590 ng/ml was reached at the end of fosnetupitant infusion, with a mean exposure (AUC∞) of 15,588 h∙ng/ml.","Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404621/),[ng] / [ml],590,200927,DB00377,Palonosetron
,31404621,exposure (AUC∞),"Netupitant was rapidly released from its prodrug and Cmax of 590 ng/ml was reached at the end of fosnetupitant infusion, with a mean exposure (AUC∞) of 15,588 h∙ng/ml.","Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404621/),[h∙ng] / [ml],"15,588",200928,DB00377,Palonosetron
,31404621,AUC∞,"Palonosetron Cmax was reached at the end of infusion, with a mean AUC∞ of 36.07 h∙ng/ml.","Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404621/),[h∙ng] / [ml],36.07,200929,DB00377,Palonosetron
,23574742,flow rate,"High-performance liquid chromatographic separation was performed on a Thermo BDS Hypersil C18 column (4.6 × 100 mm, 2.4 µm) with methanol-water (55:45, v/v) containing 0.1% formic acid and 0.2% ammonium acetate as the mobile phase, using isocratic elution at a flow rate of 0.7 mL/min.",LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574742/),[ml] / [min],0.7,242450,DB00377,Palonosetron
